netFormulary NHS
Milton Keynes Formulary
Milton Keynes University Hospital NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes Clinical Commissioning Group
Milton Keynes Community Health Services
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

 

NHS Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation B04/P/a

Contacting Milton Keynes Hospital

      
For Haematology and Oncology:

  • During hours: Macmillan Unit on 01908 243671; Internal Ext 5111 or 5112
  • Out of hours: Advanced Nurse Practitioner on bleep 1090    

Paediatric patients:

  • During hours: Paediatric Day Community Unit on 01908 242703; Internal Ext 2703      

Pharmacy:

  • Cancer and Aseptic Services Manager on bleep 1721
  • Aseptic Unit 01908 243952
  • On-call pharmacist via switchboard 01908 660033
Chapter Links...
 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
Cytotoxic Drug Aflibercept (Zaltrap®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Solution for infusion 25mg/ml; 4ml and 8ml vials

 

 
Link  MHRA Drug Safety Update (April 2016)
Link  NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Link  Visual impairment due to mycopic choroidal neovascularisation: afibercept
   
Alectinib (Alecensa®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

Capsules 150mg

 

 
Link  NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
   
AtezolizumabBlack Triangle (Tecentriq®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
  • 1200mg/20ml concentrate for solution for infusion vial
  • 840mg/14ml concentrate for solution for infusion vial 

 

 
Link  NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Link  NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Link  NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy.
Link  NICE TA584:Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
Link  NICE TA618: Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)
Link  NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
Link  NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
Link  NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
   
Axitinib (Inlyta®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Inlyta® Tablet 1mg, 3mg, 5mg, 7mg

 

 
Link  NICE TA333: Axitinib for advanced renal cell carcinoma
   
Binimetinib
View adult BNF View SPC online View childrens BNF
Formulary
Red

Tablet 45mg

 

 
Link  NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
   
Bosutinib (Bosulif®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Bosulif® Tablets 100mg, 500mg

 

 
Link  NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
   
Carfilzomib (Kyprolis®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

10mg, 30mg, 60mg vial, powder for solution for infusion

 
Link  NICE TA457:Carfilzomib for previously treated multiple myeloma
Link  NICE TA657: Carfilzomib for previously treated multiple myeloma
Link  NICE TA695: Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma
   
Ceritinib (Zykadia)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Zykadia® Capsule 150mg

 

 
Link  NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Link  NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
   
Dabrafenib (Tafinlar®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Capsule 50mg, 75mg

 

 
Link  NICE TA321:Dabrafenib for BRAF V600 +ve melanoma
Link  NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Link  NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
   
Dacomitinib
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
   
Dacomitinib monohydrate (Vizimpro®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Tablets 15 mg, 30 mg, 45 mg.

 
Link  NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
   
Daratumumab (Darzalex®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Darzalex® 20mg/mL concentrate for solution for infusion

 

 
Link  Risk of reactivation of hepatitis B virus, HCP letter (2019)
Link  NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Link  NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
Link  NICE TA634: Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal)
   
EncorafenibBlack Triangle (Braftovi®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

Capsules 50mg, 75mg

 
Link  NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
Link  NICE TA668: Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
   
Cytotoxic Drug Eribulin (Halaven®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Halaven® Injection, 0.44mg/mL solution in vial

 

 
Link  NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Link  NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
   
Gemtuzumab ozogamicin  (Mylotarg®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

5mg powder for concentrate for solution for infusion vials

 
Link  NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
   
Ibrutinib (Imbruvica®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Imbruvica® Capsules 140mg

 

 

 
Link  
Link  MHRA Drug Safety Update (August 2017)
Link  NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Link  NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Link  NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Link  NICE TA608 terminated appraisal Ibrutinib with rituximab for treating Waldenstrom’s macroglobulinaemia
   
Idelalisib (Zydelig®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Zydelig® Tablet film-coated 100mg, 150mg

 
Link  NICE TA604: Idelalisib for treating refractory follicular lymphoma
Link  NICA TA359: Chronic lymphocytic leukaemia - Idelalisib
Link  MHRA Drug Safety Update (Sept 2016)
   
Inotuzumab Ozogamicin (Besponsa®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

1mg powder for solution for infusion

 
Link  NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
   
Ixazomib (Ninlaro®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

Ninlaro® Capsules 2.3mg, 3mg, 4mg

 

 
Link  NICE: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA505)
   
Lenvatinib
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Kisplyx® Capsules 4mg, 10mg
Lenvima® Capsules 4mg, 10mg

 

 
Link   NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma (December 2018)
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
   
Midostaurin (Rydapt®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Rydapt® Capsules 25mg

 

 
Link  NICE TA523 - untreated acute myeloid leukaemia
   
Olaratumab (Lartruvo®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Lartruvo® 10mg/mL concentrate for solution for infusion in vial

 

 
Link  NICE TA465 (Guidance withdrawn) Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
   
Cytotoxic Drug Panitumumab (Vectibix®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Vectibix® Concentrate for solution for infusion 100mg/5mL, 400mg/20mL vials

Notes:

NICE does not recommend panitumumab on its own for people with
metastatic colorectal cancer that has progressed after first-line chemotherapy.

Not recommended as per NICE TA242 Colorectal cancer (metastatic) 2nd line -
cetuximab, bevacizumab and panitumumab (review) (January 2012)

 
Link  Drug Safety Update: Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis
Link  NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
   
Cytotoxic Drug Panobinostat (Farydak®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Farydak® Capsule 10mg, 15mg, 20mg

 

 
Link  NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
   
Pembrolizumab (Keytruda®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Keytruda® 25mg/mL (100mg/4ml) concentrate for solution for infusion vial

To be used in line with the NICE TA's - see links below.

May be funded through the Cancer Drugs Fund for certain indications - see links below.

NB: NICE TA 692 - NOT RECOMMENDED.

 
Link  NICE TA357: Pembrolizumab for melanoma after ipilimumab
Link  NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Link  NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Link  NICE TA447: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Link  NICE TA522: Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Link  NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Link  NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
Link  NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
Link  NICE TA650: Pembrolizumab with axitinib for untreated advanced renal cell carcinoma
Link  NICE TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
Link  NICE TA674: Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)
Link  NICE TA683: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
Link  NICE TA692: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Link  MHRA Drug Safety Update (July 2017)
   
Ponatinib (Iclusig®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Tablet 15mg,30mg,45mg

 

 
Link  Drug Safety Update : Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis
Link  MHRA Drug Safety Update (Apr 2017)
Link  NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
   
Ruxolitinib (Jakavi®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Tablet 5mg,10mg,15mg,20mg.

 

 
Link  NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
   
Trametinib (Mekinist®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Tablet 500 microgram, 2 mg

 

 
Link  Letter sent to healthcare professionals in February 2016
Link  NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Link  NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Link  Risk of gastrointestinal perforation and colitis
   
Trifluridine-tipiracil (Lonsurf®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Tablets, 15mg/6.14mg, 20mg/8.19mg

Note: Not recommended for use in children

 
Link  NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Link  NICE TA669: NOT RECOMMENDED: Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies
   
VenetoclaxBlack Triangle (Venclyxto®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Tablet 10mg, 50mg, 100mg

 
Link  NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
Link  NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
Link  NICE TA663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
   
08.01.05  Expand sub section  Amsacrine
Cytotoxic Drug Amsacrine (Amsidine®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

Concentrate for IV infusion 75mg in 1.5mL

 
   
08.01.05  Expand sub section  Arsenic trioxide
Cytotoxic Drug Arsenic Trioxide (Trisenox®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Trisenox® Injection 10mg/10mL concentrate for solution for infusion ampoules

 

 
Link  NICE TA526: treatment for acute promyelocytic leukaemia
   
08.01.05  Expand sub section  Bevacizumab
Bevacizumab (Avastin®)
(Oncology)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Bevacizumab is recommended for use in wet AMD
Avastin® Concentrate for IV infusion, 25mg in 1mL (100mg/4mL,
400mg/16mL vials)

 

 
Link  MHRA advice: Risk of osteonecrosis of the jaw ( 2011)
Link  NICE Evidence summary: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Link  NICE TA118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
Link  NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
Link  NICE TA214: Breast Cancer with taxane
Link  NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pan
Link  NICE TA263: Breast cancer with capecitabine
Link  NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Link  NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
   
08.01.05  Expand sub section  Bexarotene to top
08.01.05  Expand sub section  Bortezomib
Cytotoxic Drug Bortezomib
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Injection 3.5mg

 

 
Link  MHRA - risk of cracked or broken vials - July 2014
Link  NICE TAG129: Multiple myeloma - bortezomib
Link  NICE TAG228: 1st line treatment of multiple myeloma
Link  NICE TAG311: Bortezomib for induction therapy in multiple myeloma
Link  NICE TAG370: Bortezomib for previously untreated mantle cell lymphoma
   
08.01.05  Expand sub section  Brentuximab vedotin
Brentuximab vedotinBlack Triangle (Adcetris®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Adcetris®, 50mg powder for concentrate for solution for infusion in
vial

 
Link  NICE TA446: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Link  NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Link  NICE TA524: for treating CD30-positive Hodgkin lymphoma
Link  NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
Link  NICE TA594: Terminated appraisal Brentuximab vedotin for untreated advanced Hodgkin lymphoma
Link  NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
   
IsatuximabBlack Triangle (Sarclisa®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

20mg/mL, concentrate for solution for infusion vial, 5ml and 25ml vials.

 
Link  NICE TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
   
08.01.05  Expand sub section  Cetuximab
Cetuximab (Erbitux®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Erbitux® Intravenous Infusion, 5mg/mL in vial

 

 
Link  MHRA: importance of establishing wild type RAS (KRAS and NRAS) status before treatment of metastatic colorectal cancer
Link  NICE TA145: Head and neck cancer - cetuximab
Link  NICE TA176: Colorectal cancer (first line) - cetuximab
Link  NICE TA242 : Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pa
Link  NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Link  NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
   
08.01.05  Expand sub section  Crisantaspase
Crisantaspase (Erwinase®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

Injection, powder for reconstitution 10000 unit vial

 
   
08.01.05  Expand sub section  Dacarbazine and Temozolomide to top
Cytotoxic Drug Dacarbazine
View adult BNF View SPC online View childrens BNF
Formulary
Red

Injection, powder for reconstitution 100mg, 200mg, 500mg, 1g vial

 
   
Cytotoxic Drug Temozolomide
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Capsule 5mg, 20mg, 100mg, 140mg, 180mg, 250mg

 

 
Link  MHRA: risk of hepatic injury, including fatal hepatic failure
Link  NICE TA121: Glioma (newly diagnosed and high grade)
Link  NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
   
08.01.05  Expand sub section  Erlotinib
EntrectinibBlack Triangle (Rozlytrek®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

100mg, 200mg capsules

 
Link  NICE TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
Link  NICE TA644: Entrectinib for treating NTRK fusion-positive solid tumours
   
Erlotinib (Tarceva® )
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Tarceva® Tablet film coated 25mg, 100mg, 150mg

 

 
Link  Drug Safety Update : Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis
Link  NICE TA227: Lung cancer (non-small-cell) maintenance - erlotinib
Link  NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
08.01.05  Expand sub section  Hydroxycarbamide
Cytotoxic Drug Hydroxycarbamide
View adult BNF View SPC online View childrens BNF
Formulary
Amber 3

Capsule 500mg

Note:
To be prescribed generically for all indications

 
   
08.01.05  Expand sub section  Imatinab
08.01.05  Expand sub section  Ipilimumab
Ipilimumab (Yervoy®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Yervoy® Concentrate for Intravenous Infusion 5mg/mL: 10mL, 40mL vial

 

 
Link  MHRA: risk of CMV gastrointestinal infection with ipilimumab
Link  NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Link  NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Link  NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
   
08.01.05  Expand sub section  Mitotane to top
08.01.05  Expand sub section  Panitumumab
08.01.05  Expand sub section  Pentostatin
Cytotoxic Drug Pentostatin (Nipent®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

Injection, powder for reconstitution 10mg vial

 
   
08.01.05  Expand sub section  Platinum compounds
Cytotoxic Drug Carboplatin
View adult BNF View SPC online View childrens BNF
Formulary
Red

Injection 50mg in 5mL, 450mg in 45mL, 600mg in 60mL

 

 
Link  NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Link  NICE TA285: Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
   
Cytotoxic Drug Cisplatin
View adult BNF View SPC online View childrens BNF
Formulary
Red

Injection 10mg in 10mL, 50mg in 50mL, 100mg in 100mL

 
   
Cytotoxic Drug Oxaliplatin
View adult BNF View SPC online View childrens BNF
Formulary
Red

Injection 50mg, 100mg vial

 

 
Link  NICE CG131: Colorectal cancer: diagnosis and management
Link  NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
   
08.01.05  Expand sub section  Porfimer sodium and temoporfin
08.01.05  Expand sub section  Procarbazine to top
Cytotoxic Drug Procarbazine
View adult BNF View SPC online View childrens BNF
Formulary
Red

Capsule 50mg

Note:
Procarbazine is a mild monoamine-oxidase inhibitor but dietary restriction is not
considered necessary. Alcohol ingestion may cause a disulfiram-like reaction.

 
   
08.01.05  Expand sub section  Protein kinase inhibitors
Abemaciclib (Verzenios®)
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Tablet 150mg

 

 
Link  NICE TA563:Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
   
AcalabrutinibBlack Triangle (Calquence®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Capsules 100mg

For use in accordance with the NICE TA (see link below).

 
Link  NICE TA689: Acalabrutinib for treating chronic lymphocytic leukaemia
   
Afatinib (Giotrif®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Tablet 20mg, 30mg, 40mg, 50mg

 

 
Link  NICE TA310: Afatinib for non-small-cell lung cancer
   
BrigatinibBlack Triangle (Alunbrig®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Tablets, 30mg, 90mg, 180mg

 
Link  NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
Link  NICE TA670: Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor
   
Cabozantinib (Cometriq®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Cometriq® Capsules 20mg, 80mg
Cabometyx® 20mg, 40mg, 60mg tablets

Notes:

NHSE Position Statement.

 
Link  NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Link  NICE TA516: Cabozantinib for treating medullary thyroid cancer
Link  NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
   
Crizotinib (Xalkori®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Xalkori® Capsules 200mg, 250mg

 

 
Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
Link  MHRA: risk of cardiac failure with crizotinib
   
Dasatinib (Sprycel®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Sprycel® Tablets film-coated 20mg, 50mg, 80mg, 100mg, 140mg

 

 
Link  MHRA/CHM advice (May 2016): Risk of hepatitis B virus reactivation with BCR-ABL tyrosine kinase inhibitors
Link  NICE TA425:Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426:Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Everolimus (Afinitor®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Afinitor® Tablets 2.5mg, 5mg, 10mg
Certican® Tablets 250 microgram, 750 microgram

 

 
Link  NICE TA348: Preventing Rejection in Liver Transplant
Link  NICE TA421:Everolimus with exemestane in advanced breast cancer after endocrine therapy
Link  NICE TA432:Everolimus for advanced renal cell carcinoma after previous treatment
Link  NICE TA449:Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Link  NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Link  NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
   
Gefitinib (Iressa®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Tablets 250mg

 

 
Link  Drug Safety Update: Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis
Link  NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer
   
GilteritinibBlack Triangle (Xospata®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

40mg tablets

 
Link  NICE TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
   
Imatinib
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Glivec® Tablets film-coated 100mg, 400mg

 

 
Link  NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
Link  NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Link  NICE TA425:Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426:Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Link  NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia
Link  NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
   
Lapatinib (Tyverb®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Tablet 250mg

 

 
Link  NICE TA257 Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER
   
Nilotinib (Tasigna®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Capsules 150mg, 200mg

 

 
Link  NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Link  NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML
Link  NICE TA425:Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426:Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
OsimertinibBlack Triangle (Tagrisso®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Tablet 40mg, 80mg 

 
Link  NICE TA416: Osimertinib in non-small-cell lung cancer
Link  NICE TA621: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
Link  NICE TA653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer
Link  NICE TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
   
Pazopanib (Votrient®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Tablet 200mg,400mg

 

 
Link  NICE TA 215: Pazopanib in renal cell cancer
   
Regorafenib (Stivarga® )
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Tablets 40mg

 

 
Link  NICE TA488:Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Link  NICE TA514: Regorafenib for previously treated advanced hepatocellular carcinoma
Link  NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
   
Sorafenib (Nexavar®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Tablet 200mg

 

 
Link  NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Link  NICE TA535: Sorafenib for treating differentiated thyroid cancer after radioactive iodine.
   
Sunitinib (Sutent®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Capsules 12.5mg,25mg,50mg

 
Link  NICE TA169: Renal cell carcinoma - sunitinib
Link  NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA179: Gastrointestinal stromal tumours - sunitinib
Link  NICE TA449:Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
   
Cytotoxic Drug Temsirolimus (Torisel®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Solution for infusion 25mgper 1ml

 

 
Link  NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
   
Vemurafenib (Zelboraf®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Tablet 240mg

 

 
Link  MHRA: Risk of potentiation of radiation toxicity with vemurafenib
Link  NICE TA269: Vemurafenib for treating malignant melanoma
   
08.01.05  Expand sub section  Taxanes
Cytotoxic Drug Cabazitaxel (Jevtana®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Jevtana® 40mg/mL, (60mg/1.5-mL) Concentrate and solvent for solution for
infusion vials

Notes:
Incompatible with PVC.

Solvent contains ethanol

 

 
Link  NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
   
Cytotoxic Drug Docetaxel (Taxotere®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

Concentrate for IV infusion 80mg in 2mL

Notes:
Dexamethasone by mouth 8mg bd for 3 days, starting on the day before each
course of docetaxel, is recommended for reducing fluid retention and
hypersensitivity reactions.

 

 
Link  NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Link  NICE TA109: Breast cancer (early) - docetaxel
Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
   
Cytotoxic Drug Paclitaxel
View adult BNF View SPC online View childrens BNF
Formulary
Red

Concentrate for solution for infusion vials:

30mg/5ml vial

100mg/16.7ml vial

150mg/25ml vial

300mg/50ml vial

 
Link  NICE TA108: Breast cancer (early) - paclitaxel
Link  NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
   
Cytotoxic Drug Paclitaxel - Albumin Bound Formulation (Abraxane®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Intravenous infusion, powder for suspension for infusion:

100mg vials, 250mg vials

 
Link  NICE TA108: Paclitaxel for the adjuvant treatment of early node-positive breast cancer
Link  NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Link  NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Link  NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Link  NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
   
08.01.05  Expand sub section  Topoisomerase I inhibitors
Cytotoxic Drug Topotecan (Hycamtin®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

Hycamtin® Capsule 250 microgram, 1mg
Hycamtin® IV Infusion, powder for reconstitution, 1mg, 4mg vials
Concentrate for Intravenous Infusion 1mg/mL: 1mL, 4mL vials

 

 
Link  NICE TA183: Cervical cancer (recurrent) - topotecan
Link  NICE TA184: Lung cancer (small-cell) - topotecan
Link  NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
   
08.01.05  Expand sub section  Trabectedin
Cytotoxic Drug Trabectedin (Yondelis®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

Yondelis® Injection, powder for concentrate for solution for infusion, 250
microgram, 1mg vials

 

 
Link  NICE TA185: Soft tissue sarcoma - trabectedin
Link  NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
   
08.01.05  Expand sub section  Trastuzumab to top
Cytotoxic Drug Pertuzumab (Perjeta®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Perjeta® Injection, 420mg/14mL concentrate for solution for infusion in vial

 

 
Link  NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Link  NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
   
Cytotoxic Drug Trastuzumab (Herceptin®)
(Intravenous)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Herceptin® Intravenous Infusion 150mg vial

 

 
Link  NICE TA34: Breast cancer - trastuzumab
Link  NICE TA107: Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
Link  NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
   
Cytotoxic Drug Trastuzumab emtansine (Kadcyla®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Kadcyla® Injection 100mg, 160mg Powder for concentrate for solution for
infusion vial

 

 
Link  NICE TA458:Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
Link  NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
   
08.01.05  Expand sub section  Tretinoin
Tretinoin
View adult BNF View SPC online View childrens BNF
Formulary
Red

Capsule 10mg

 
   
08.01.05  Expand sub section  Vismodegib
Cytotoxic Drug Vismodegib (Erivedge®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Capsule 150mg



 
Link  NICE TA489: Vismodegib for treating basal cell carcinoma
   
 ....
 Non Formulary Items
Bexarotene  (Targretin®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Cabozantinib  (Cabometyx®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Link  NICE TA463:Cabozantinib for previously treated advanced renal cell carcinoma
Link  NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
 
Elotuzumab  (Empliciti®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Cytotoxic Drug  Irinotecan Hydrochloride

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Cytotoxic Drug  Irinotecan hydrochloride trihydrate  (Onivyde®)
(pegylated liposomal)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Lenvatinib  (Lenvima®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Cancer Drugs Fund
Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Link  NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma
 
Mitotane  (Lysodren®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Necitumumab  (Portrazza®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Link  NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
 
Porfimer Sodium  (Photofrin ®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Ramucirumab  (Cyramza®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Link  
Link  NICE TA403:Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
Link  NICE TA609 terminated appraisal Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib
Link  NICE TA635: Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal)
 
Rociletinib

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Sonidegib  (Odomzo®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Temoporfin  (Foscan®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Cytotoxic Drug  Trastuzumab  (Herceptin®)
(Subcutaneous)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Homecare
Link  NICE TA34: Breast cancer - trastuzumab
Link  NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
 
Cytotoxic Drug  Trastuzumab  (Ontruzant®)
(IV Biosimilar)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Link  NICE TA34: Breast cancer - trastuzumab
Link  NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
 
Cytotoxic Drug  Vandetanib  (Caprelsa®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Vosaroxin  (Qinprezo)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Green

Routine prescribing within licensed indication  

Amber 1

Specialist recommendation followed by GP initiation and continuation  

Amber 2

Specialist or GP initiation in line with local guideline after 1st line failure followed by GP continuation   

Amber 3

Specialist initiation and stabilisation followed by GP continuation  

Amber SCG

Specialist initiation and stabilisation followed by GP continuation in line with an agreed shared care guideline  

Red

Hospital or specialist prescribing only  

Red Red

These medicines have been evaluated and rejected by MKPAG and are NOT approved for use within MK. They are not recommended for use because of lack of clinical effectiveness, cost effectiveness or safety.  

netFormulary